{
  "id": "976607c3ccc089b8",
  "title": "Pharming Group N . V .: Pharming Group receives Complete Response Letter from U . S . FDA for sNDA for Joenja ( leniolisib ) in children aged 4 to 11 years with APDS",
  "description": "20260201T233000Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2026-02/67582102-pharming-group-n-v-pharming-group-receives-complete-response-letter-from-u-s-fda-for-snda-for-joenja-leniolisib-in-children-aged-4-to-11-years-wi-399.htm",
  "published_at": "20260201T233000Z",
  "fetched_at": "2026-02-02T00:29:20.107852+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2026-02/67582102-pharming-group-n-v-pharming-group-receives-complete-response-letter-from-u-s-fda-for-snda-for-joenja-leniolisib-in-children-aged-4-to-11-years-wi-399.htm",
    "url_mobile": "",
    "title": "Pharming Group N . V .: Pharming Group receives Complete Response Letter from U . S . FDA for sNDA for Joenja ( leniolisib ) in children aged 4 to 11 years with APDS",
    "seendate": "20260201T233000Z",
    "socialimage": "https://www.finanznachrichten.de/chart-pharming-group-nv-aktie-intraklein-tradegate.png",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}